Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Baerlocher GM, Burington B, Snyder DS.

N Engl J Med. 2015 Dec 24;373(26):2580. doi: 10.1056/NEJMc1512663. No abstract available.

2.

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

El Fassi D.

N Engl J Med. 2015 Dec 24;373(26):2579. doi: 10.1056/NEJMc1512663. No abstract available.

PMID:
26699177
3.

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Tefferi A.

N Engl J Med. 2015 Dec 24;373(26):2580-1. doi: 10.1056/NEJMc1512663. No abstract available.

PMID:
26709404
4.

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Bjørn ME, Nielsen CH, Hasselbalch HC.

N Engl J Med. 2015 Dec 24;373(26):2579-80. doi: 10.1056/NEJMc1512663. No abstract available.

PMID:
26699178
5.

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A, Daskalakis M, Burington B, Stuart M, Snyder DS.

N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479.

6.

Treating Myeloproliferation--On Target or Off?

Armanios M, Greider CW.

N Engl J Med. 2015 Sep 3;373(10):965-6. doi: 10.1056/NEJMe1508740. No abstract available.

PMID:
26332552
7.

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A.

N Engl J Med. 2015 Sep 3;373(10):908-19. doi: 10.1056/NEJMoa1310523.

8.

Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.

Hu Y, Bobb D, Lu Y, He J, Dome JS.

Cancer Genet. 2014 Sep;207(9):403-11. doi: 10.1016/j.cancergen.2014.09.002. Epub 2014 Sep 16.

PMID:
25441685
9.

The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.

Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, Wright WE, Shay JW, Go NF.

Cancer Res. 2010 Nov 15;70(22):9494-504. doi: 10.1158/0008-5472.CAN-10-0233. Epub 2010 Nov 9.

10.

A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM.

Clin Cancer Res. 2013 Dec 1;19(23):6578-84. doi: 10.1158/1078-0432.CCR-13-1117. Epub 2013 Oct 4.

11.

The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.

Hu Y, Bobb D, He J, Hill DA, Dome JS.

Cancer Biol Ther. 2015;16(6):949-57. doi: 10.1080/15384047.2015.1040964. Epub 2015 Apr 28.

12.

Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.

Wu X, Smavadati S, Nordfjäll K, Karlsson K, Qvarnström F, Simonsson M, Bergqvist M, Gryaznov S, Ekman S, Paulsson-Karlsson Y.

Biochim Biophys Acta. 2012 Dec;1823(12):2130-5. doi: 10.1016/j.bbamcr.2012.08.003. Epub 2012 Aug 11.

13.

Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.

Mosoyan G, Kraus T, Ye F, Eng K, Crispino JD, Hoffman R, Iancu-Rubin C.

Leukemia. 2017 Nov;31(11):2458-2467. doi: 10.1038/leu.2017.78. Epub 2017 Mar 8.

14.

The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.

Koziel JE, Herbert BS.

Breast Cancer Res Treat. 2015 Feb;149(3):607-18. doi: 10.1007/s10549-015-3270-1. Epub 2015 Jan 28.

15.

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH.

Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2.

16.

Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.

Mender I, Senturk S, Ozgunes N, Akcali KC, Kletsas D, Gryaznov S, Can A, Shay JW, Dikmen ZG.

Int J Oncol. 2013 May;42(5):1709-15. doi: 10.3892/ijo.2013.1865. Epub 2013 Mar 27.

17.

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R.

J Neurooncol. 2016 Sep;129(3):443-451. doi: 10.1007/s11060-016-2189-7. Epub 2016 Jun 27.

18.

Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.

Ferrandon S, Malleval C, El Hamdani B, Battiston-Montagne P, Bolbos R, Langlois JB, Manas P, Gryaznov SM, Alphonse G, Honnorat J, Rodriguez-Lafrasse C, Poncet D.

Mol Cancer. 2015 Jul 17;14:134. doi: 10.1186/s12943-015-0376-3.

19.

Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.

Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S, Elizabeth C, Yu M, Luu B, Morrison A, Adamski J, Nethery-Brokx K, Li XN, Van Meter T, Dirks PB, Rutka JT, Taylor MD, Tabori U, Hawkins C.

Acta Neuropathol. 2014 Dec;128(6):863-77. doi: 10.1007/s00401-014-1327-6. Epub 2014 Aug 6.

20.

A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).

Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, Goldberg JD, Hoffman R.

Leuk Res. 2017 Feb;53:13-19. doi: 10.1016/j.leukres.2016.11.015. Epub 2016 Nov 30.

PMID:
27930945

Supplemental Content

Support Center